|Bid||0.00 x 900|
|Ask||0.00 x 2900|
|Day's Range||43.07 - 44.56|
|52 Week Range||33.20 - 46.47|
|Beta (3Y Monthly)||0.75|
|PE Ratio (TTM)||11.21|
|Earnings Date||Jan 28, 2019 - Feb 1, 2019|
|Forward Dividend & Yield||1.36 (3.02%)|
|1y Target Est||44.59|
Endo International’s (ENDP) next two business segments are: The US Generic Pharmaceuticals segment includes solid oral extended release, solid oral immediate release, abuse-deterrent products, liquids, semi-solids, patches, powders, ophthalmics, and sprays. Revenues from this segment declined from $294.75 million in the third quarter of 2017 to $257.97 million in the third quarter of 2018. The International Pharmaceuticals segment revenues also declined from $56.43 million in the third quarter of 2017 to $30.25 million in the third quarter of 2018.
Pfizer (NYSE:PFE) may find itself doing something it has not done in years—break records. The New York-based pharmaceutical giant found itself stuck as PFE stock spent years mired in a trading range. Now it looks poised to reach and surpass the highs that have eluded Pfizer for almost two decades.
Shares of generic drug makers fell sharply Monday, after a Washington Post report that an antitrust lawsuit brought by states over two drugs in 2016 has expanded into a major probe of alleged price-fixing. The case now involves at least 16 companies and 300 drugs, the report said, citing Joseph Nielsen, an assistant attorney general and antitrust investigator in Connecticut, who has been a leader in the probe. Nielsen is quoted as saying, "this is most likely the largest cartel in the history of the United States." The victims were consumers and taxpayers, who have been carrying the high cost of overcharges on common antiboitics, blood-pressure medications, arthritis treatments, anxiety pills and more, said the report. Teva Pharmaceuticals Industries Ltd. ADRs fell 5.7% on the news. Mylan NV was down 4.6%, and Dr. Reddy Labs Ltd was down 3%. Abbott Labs was down 1.4% and Pfizer Inc. was down 1.6%. The S&P 500 was down 1.8% and the Dow Jones Industrial Average was down about 2%.
The last week of November was a good one for Antares Pharma, Inc. (ATRS) with both Epi Pen and Xyosted now commercially available. Teva Pharmaceuticals (TEVA) announced on November 27th that the recently approved AB-rated generic Epinephrine Pen is now available in the United States. For the remainder of 2018, only the Epi Pen 0.3 mg version will be available in limited quantities with additional supply of the 0.3 mg version and Epi Pen Jr (0.15 mg) to be available in 2019.
Before we spend many hours researching a company, we’d like to analyze what insiders, hedge funds and billionaire investors think of the stock first. We would like to do so because the elite investors’ consensus returns have been exceptional. In the following paragraphs, we find out what the billionaire investors and hedge funds think of […]
Conatus' (CNAT) emricasan fails to meet the primary endpoint in a phase IIb study on compensated NASH cirrhosis patients at high risk of decompensation.
The company gave a nonprofit foundation money to cover Medicare copays for its pulmonary arterial hypertension drugs as it hiked the prices of those drugs and steered Medicare patients away from the company's own free drug program to the foundation.
Exelixis (EXEL) and its partner announce initiation of a pivotal study to evaluate its kidney cancer drug, Cabometyx, in combination with Roche's Tecentriq in liver cancer.
Health-care stocks have found new life as markets crater. UnitedHealth UNH and Eli Lilly LLY roared to record highs on Tuesday, while Pfizer PFE and Merck MRK moved to their highest levels since 2001, although they were all down at least 1 percent in Thursday's premarket. Mark Newton , technical analyst at Newton Advisors, said Tuesday the overall health-care trade still looks like a solid play.
CSPC Pharmaceutical Group Ltd., which is bidding to provide drugs to Chinese cities in the program, tumbled 14 percent at the close in Hong Kong Thursday, its biggest decline since 2008. The MSCI China Health Care Index fell 8.4 percent, the biggest decline since 2009.
NEW YORK, NY / ACCESSWIRE / December 5, 2018 / U.S. equities plunged on Tuesday as skepticism over the U.S. and China’s ability to close a trade agreement weighed on the markets. The Dow Jones Industrial ...
AI is the buzzword these days, and the market has huge growth potential. PR Newswire, citing QY Research, reported that the global AI market could grow 52.6% (compounded annually) from $2.65 billion in 2017 to $78 billion by 2025. IBM (IBM) has been the largest player in the AI market.
U.S. stock futures and options trading volume are galloping higher following a promising turn in the trade war. During their meeting at the G-20 summit over the weekend, President Donald Trump and Chinese president Xi Jinping agreed to halt additional tariffs after Jan. 1.
By Brian Marckx, CFA NASDAQ:DARE READ THE FULL DARE RESEARCH REPORT Q3 / Pipeline Update Daré (NASDAQ:DARE) reported financial results for their third quarter and provided an operational update. Relative ...
NEW YORK-- -- 26-week data from the ongoing 52-week REFLECTIONS B328-06 study met its primary endpoint, demonstrating comparable safety and efficacy for patients with indolent follicular lymphoma The U.S. Food and Drug Administration accepted for review, a Biologics License Application for PF-05280586 in September 2018 Pfizer Inc. announced today at the American Society of Hematology Annual Meeting ...
Pfizer won't be able to access the U.S. market with its biosimilar version until late 2023, providing AbbVie with additional years of exclusivity and strong cash flows.